Elena H Martínez-Lapiscina1, Santiago Ortiz-Pérez2, Elena Fraga-Pumar1, Eloy Martínez-Heras1, Iñigo Gabilondo1, Sara Llufriu1, Santiago Bullich1, Marc Figueras2, Albert Saiz1, Bernardo Sánchez-Dalmau3, Pablo Villoslada4. 1. Center of Neuroimmunology and Department of Neurology, Hospital Clinic of Barcelona, Spain. 2. Department of Ophthalmology, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain. 3. Center of Neuroimmunology and Department of Neurology, Hospital Clinic of Barcelona, Spain Department of Ophthalmology, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain. 4. Center of Neuroimmunology and Department of Neurology, Hospital Clinic of Barcelona, Spain pvilloslada@clinic.ub.es.
Abstract
BACKGROUND: Colour vision assessment correlates with damage of the visual pathway and might be informative of overall brain damage in multiple sclerosis (MS). OBJECTIVE: The objective of this paper is to investigate the association between impaired colour vision and disease severity. METHODS: We performed neurological and ophthalmic examinations, as well as magnetic resonance imaging (MRI) and optical coherence tomography (OCT) analyses, on 108 MS patients, both at baseline and after a follow-up of one year. Colour vision was evaluated by Hardy, Rand and Rittler plates. Dyschromatopsia was defined if colour vision was impaired in either eye, except for participants with optic neuritis (ON), for whom only the unaffected eye was considered. We used general linear models adjusted for sex, age, disease duration and MS treatment for comparing presence of dyschromatopsia and disease severity. RESULTS: Impaired colour vision in non-ON eyes was detected in 21 out of 108 patients at baseline. At baseline, patients with dyschromatopsia had lower Multiple Sclerosis Functional Composite (MSFC) scores and Brief Repeatable Battery-Neuropsychology executive function scores than those participants with normal colour vision. In addition, these patients had thinner retinal nerve fiber layer (RNFL), and smaller macular volume, normalized brain volume and normalized gray matter volume (NGMV) at baseline. Moreover, participants with incident dyschromatopsia after one-year follow-up had a greater disability measured by the Expanded Disability Status Scale and MSFC-20 and a greater decrease in NGMV than participants with normal colour vision. CONCLUSIONS: Colour vision impairment is associated with greater MS severity.
BACKGROUND: Colour vision assessment correlates with damage of the visual pathway and might be informative of overall brain damage in multiple sclerosis (MS). OBJECTIVE: The objective of this paper is to investigate the association between impaired colour vision and disease severity. METHODS: We performed neurological and ophthalmic examinations, as well as magnetic resonance imaging (MRI) and optical coherence tomography (OCT) analyses, on 108 MS patients, both at baseline and after a follow-up of one year. Colour vision was evaluated by Hardy, Rand and Rittler plates. Dyschromatopsia was defined if colour vision was impaired in either eye, except for participants with optic neuritis (ON), for whom only the unaffected eye was considered. We used general linear models adjusted for sex, age, disease duration and MS treatment for comparing presence of dyschromatopsia and disease severity. RESULTS:Impaired colour vision in non-ON eyes was detected in 21 out of 108 patients at baseline. At baseline, patients with dyschromatopsia had lower Multiple Sclerosis Functional Composite (MSFC) scores and Brief Repeatable Battery-Neuropsychology executive function scores than those participants with normal colour vision. In addition, these patients had thinner retinal nerve fiber layer (RNFL), and smaller macular volume, normalized brain volume and normalized gray matter volume (NGMV) at baseline. Moreover, participants with incident dyschromatopsia after one-year follow-up had a greater disability measured by the Expanded Disability Status Scale and MSFC-20 and a greater decrease in NGMV than participants with normal colour vision. CONCLUSIONS:Colour vision impairment is associated with greater MS severity.
Authors: Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon Journal: Neurology Date: 2019-04-10 Impact factor: 9.910
Authors: Elena H Martinez-Lapiscina; Maria Sepulveda; Ruben Torres-Torres; Salut Alba-Arbalat; Sara Llufriu; Yolanda Blanco; Ana M Guerrero-Zamora; Nuria Sola-Valls; Santiago Ortiz-Perez; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz Journal: Ther Adv Neurol Disord Date: 2016-08-15 Impact factor: 6.570
Authors: Maria Sepúlveda; Begoña Fernández-Diez; Elena H Martínez-Lapiscina; Sara Llufriu; Nuria Sola-Valls; Irati Zubizarreta; Yolanda Blanco; Albert Saiz; Dino Levy; Paul Glimcher; Pablo Villoslada Journal: Mult Scler Date: 2016-12-07 Impact factor: 6.312
Authors: Santiago Ortiz-Perez; Magí Andorra; Bernardo Sanchez-Dalmau; Rubén Torres-Torres; David Calbet; Erika J Lampert; Salut Alba-Arbalat; Ana M Guerrero-Zamora; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; María Sepúlveda; Albert Saiz; Pablo Villoslada; Elena H Martinez-Lapiscina Journal: J Neurol Date: 2016-02-09 Impact factor: 4.849
Authors: Antonio Barreiro-González; Maria T Sanz; Sara Carratalà-Boscà; Francisco Pérez-Miralles; Carmen Alcalá; Enrique España-Gregori; Bonaventura Casanova Journal: Acta Neurol Belg Date: 2020-10-12 Impact factor: 2.396
Authors: E J Lampert; M Andorra; R Torres-Torres; S Ortiz-Pérez; S Llufriu; M Sepúlveda; N Sola; A Saiz; B Sánchez-Dalmau; P Villoslada; Elena H Martínez-Lapiscina Journal: J Neurol Date: 2015-08-11 Impact factor: 4.849